{
  "id": 6272421,
  "title": "Medizin: EU genehmigt Millionen für Insulinfabrik von Sanofi in Hessen",
  "url": "https://urgent.news/2026/09/08/medizin-eu-genehmigt-millionen-fur-insulinfabrik-von-sanofi-in-hessen",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-08T11:21:15.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/unternehmen/industrie/medizin-eu-genehmigt-millionen-fuer-insulinfabrik-von-sanofi-in-hessen/100252915.html"
  },
  "original_language": "de",
  "account": "In a move to bolster insulin supply, the European Union has approved a €400 million grant for German pharmaceutical company Sanofi to build a new insulin factory in Hesse. The EU Commission stated that the German company, headquartered in Frankfurt, could be compensated for its net costs through this support. The EU body scrutinizes such state aid to prevent competitive distortions. Sanofi-Aventis Germany GmbH has committed to constructing the new insulin factory by the end of 2032 at its site in Frankfurt’s Höchst district, with annual production of at least 1.1 tonnes of insulin by 2042. The pharmaceutical manufacturer must also maintain a tonne of pharmaceutical insulin reserves and prioritize supplying European markets in the event of an insulin supply bottleneck. Without the funds, Sanofi, according to the EU announcement, would close its German operations, which are the sole producer of human insulin in the European Economic Area and one of only two insulin production sites in the region. The EU noted that some products like human insulin would no longer be produced within the EEA, leaving Europe dependent on imports from third countries. Human insulin is used to treat diabetes mellitus, a metabolic disorder characterized by elevated blood sugar levels. Insulin enables glucose to be absorbed from the blood into body cells. Sanofi announced in 2024 its intention to invest around €1.3 billion in building a modern insulin production facility at its Frankfurt site by 2029, with several hundred employees expected to work there. The company's investment is made possible through the support of the federal and Hessian governments, as well as the city of Frankfurt. Brussels' green light was the final hurdle, as the site in Frankfurt last employed around 6,500 people according to company data.",
  "summary": "Der Pharmakonzern Sanofi baut in Frankfurt eine neue Produktionsanlage für Insulin. Dafür braucht er Unterstützung – die darf Deutschland nun geben.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}